← Back to Portfolio

CRISPR Therapeutics

CRISPR Therapeutics is an early-stage biopharmaceutical company created to translate CRISPR-Cas9, a breakthrough gene-editing technology, into transformative medicines for the treatment of serious human diseases. CRISPR has formed the largest gene editing collaboration announced to date with Vertex Pharmaceuticals. The deal, worth up to $2.6 billion, will use CRISPR’s gene editing technology to discover and develop new treatments for genetic diseases.The company is working on translational development programmes in several important disease areas with collaborators in Europe and the US. CRISPR went public in October 2016.

LocationBasel, Switzerland and Cambridge, MA, USA
CEOSamarth Kulkarni
PartnerKurt von Emster